Asia Pacific Circulating Tumor Cell (CTC) Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (CTC Detection and Enrichment Method, CTC Direct Detection Method, and CTC Analysis), Application (Clinical/Liquid Biopsy,

Asia Pacific Circulating Tumor Cell (CTC) Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (CTC Detection and Enrichment Method, CTC Direct Detection Method, and CTC Analysis), Application (Clinical/Liquid Biopsy, and Research), and End-User (Hospitals and Clinics, Research and Academic Institutes, and Diagnostic Centers)

The Asia Pacific circulating tumor cell (CTC) diagnostics market is expected to reach US$ 689.3 million by 2028 from US$ 347.6 million in 2021. The market is estimated to grow at a CAGR of 10.3% from 2021 to 2028.

The rising demand for liquid biopsies for cancer detection is expected to boost the demand for circulating tumor cell diagnostics. Leading market players focus on enlarging their reach across emerging markets by expanding their distribution networks and augmenting manufacturing capabilities. Emerging markets in India and South Korea are expected to offer potential growth opportunities for crucial circulating tumor cell (CTC) diagnostics market players in the coming years. This can be attributed to the large patient population, high cancer prevalence (including types such as skin, breasts, lungs, pancreas, and other organs and glands), increasing disposable income, improving healthcare infrastructure, and growing medical tourism in these countries. As the markets mature, most players are shifting their focus to emerging markets. High investments in life science and health research in emerging countries play a key role in upgrading their healthcare infrastructure with the latest technologies. This factor, in turn, supports the progress in cancer diagnostics, thereby creating new opportunities for the Asia Pacific circulating tumor cell (CTC) diagnostics market players.

Prohibitive measures have been taken to contain the spread of the COVID-19 pandemic in APAC countries. The pandemic has largely affected the economies of India, China, Japan, and South Korea, among others. The onset of the pandemic and exponential rise in patients with the need of hospitalization led to delays and temporary suspension of cancer screening, diagnosis, and treatment services. Moreover, government regulations, nationwide lockdowns, and spiking infection rates had a significant financial impact on healthcare facilities. Several hospitals and clinics have seen a decrease in patient visits as a result of COVID-19. The scarcity of medical care and supplies for conditions other than COVID-19 had a detrimental impact on the circulating tumor cell diagnostics market proliferation. At the same time, limited healthcare staff availability hampered the circulating tumor cell diagnostics market in Asia Pacific. In addition, the socio-economy was badly hit, with growing inflation, declining GDP, and rising unemployment in the region. The pandemic has affected three main aspects of the global economy: manufacturing, supply chain, and business and financial markets.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the circulating tumor cell (CTC) diagnostics market. The Asia Pacific circulating tumor cell (CTC) diagnostics market is expected to grow at a good CAGR during the forecast period.

Asia Pacific Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Circulating Tumor Cell (CTC) Diagnostics Market Segmentation

By Technology

CTC detection and Enrichment Method CTC Direct Detection Methods CTC Analysis By Application

Clinical/Liquid Biopsy Risk Assessment Screening and Monitoring Research Cancer Stem Cell and Tumorigenesis Research Drug/Therapy Development

By End-User

Hospitals and Clinics Research and Academic Institutes Diagnostic Centers

By Country

China Japan India South Korea Australia Rest of Asia Pacific

Companies Mentioned

Thermo Fisher Scientific Inc. Stemcell Technologies Inc. Qiagen Advanced Cell Diagnostics, Inc. (Bio-Techne Corporation) Screencell Fluxion Biosciences

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific circulating tumor cell (CTC) diagnostics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific circulating tumor cell (CTC) diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.